Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, talks on the efficacy of tagraxofusp, a CD123-targeted agent, in the treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN). The approval of tagraxofusp in the US and in Europe has led to improved outcomes for these patients with a poor prognosis. In addition, a recent study demonstrated that tagraxofusp is efficacious across all age cohorts and has a similar efficacy and toxicity profile across different BPDCN subsets. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.